Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Profit After Tax: 2016-2024

Historic Profit After Tax for Cidara Therapeutics (CDTX) over the last 9 years, with Dec 2024 value amounting to -$170.3 million.

  • Cidara Therapeutics' Profit After Tax fell 420.69% to -$83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$184.8 million, marking a year-over-year decrease of 46.80%. This contributed to the annual value of -$170.3 million for FY2024, which is 578.99% down from last year.
  • Per Cidara Therapeutics' latest filing, its Profit After Tax stood at -$170.3 million for FY2024, which was down 578.99% from -$25.1 million recorded in FY2023.
  • In the past 5 years, Cidara Therapeutics' Profit After Tax registered a high of -$25.1 million during FY2023, and its lowest value of -$170.3 million during FY2024.
  • In the last 3 years, Cidara Therapeutics' Profit After Tax had a median value of -$33.6 million in 2022 and averaged -$76.3 million.
  • Per our database at Business Quant, Cidara Therapeutics' Profit After Tax skyrocketed by 41.11% in 2021 and then plummeted by 578.99% in 2024.
  • Yearly analysis of 5 years shows Cidara Therapeutics' Profit After Tax stood at -$72.1 million in 2020, then soared by 41.11% to -$42.5 million in 2021, then climbed by 20.92% to -$33.6 million in 2022, then increased by 25.32% to -$25.1 million in 2023, then slumped by 578.99% to -$170.3 million in 2024.